Analyst Ratings for Atrium Therapeutics (RNA)
RNA Rating Summary
RNA Price Target Summary
- Highest: $74.00 (TD Cowen)
- Lowest: $25.00 (Leerink)
- Average: $57.82
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$57.82 (+394.6%)
* Over Last 12-Mos
Rating Score: 4.8 / 10
Percentile Rank: 48%
Avg. $ Target:
$57.82 (+394.6%)
* Over Last 12-Mos
Rating Score: 4.8 / 10
Percentile Rank: 48%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/18/2026 | Cantor Fitzgerald | Kristen Kluska | New Coverage | Neutral (N/A) |
25.00 (N/A) |
12.48 (11.69) |
-6.33% | Details |
| 5/15/2026 | Leerink | Joseph Schwartz | New Coverage | Outperform (N/A) |
25.00 (N/A) |
13.27 (11.69) |
-11.91% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
